No Data
No Data
No Data
No Data
No Data
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
PDF Version Clinical data readout expected end of Q3 2024 SER-155 and other Seres microbiome therapeutic candidates have potential to expand microbiome therapeutic franchise into additional medic
Seres TherapeuticsApr 9 12:00
Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for Now
Yahoo FinanceMar 29 00:47
Revenues Working Against Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Share Price Following 27% Dive
To the annoyance of some shareholders, Seres Therapeutics, Inc. (NASDAQ:MCRB) shares are down a considerable 27% in the last month, which continues a horrid run for the company. The recent drop com
Simply Wall StMar 29 00:32
Seres Therapeutics Announced That On March 25, 2024, The Compensation And Talent Committee Of Seres' Board Of Directors Granted Inducement Equity Grants Of 700,000 Shares To Marella Thorell, New Executive Vice President And CFO
Seres Therapeutics Announced That On March 25, 2024, The Compensation And Talent Committee Of Seres' Board Of Directors Granted Inducement Equity Grants Of 700,000 Shares To Marella Thorell, New Execu
BenzingaMar 28 19:26
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 19, 2024-- Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that
Seres TherapeuticsMar 19 12:00
11 Oversold NASDAQ Stocks To Buy Right Now
Yahoo FinanceMar 14 03:32
No Data
No Data